✦ LIBER ✦

ANALYSIS OF MULTIPLE FAILURE TIME DATA FROM AN AIDS CLINICAL TRIAL

✍ Scribed by DIANNE M. FINKELSTEIN; DAVID A. SCHOENFELD; EVA STAMENOVIC

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 205 KB
Volume: 16
Category: Article
ISSN: 0277-6715
DOI: 10.1002/(sici)1097-0258(19970430)16:8<951::aid-sim547>3.0.co;2-5

No coin nor oath required. For personal study only.

✦ Synopsis

The primary endpoint of AIDS prophylaxis trials is the occurrence of opportunistic infections. While the treatments are not expected to have an effect on the underlying HIV disease, an effect of treatments on mortality cannot be ruled out. Therefore, the primary analysis of these trials must be based on a combined endpoint of infection and survival times. There are several methods available for analysis of multiple failure time data. However, there is no standard method for combining mortality and other failures in these analyses. This paper explores the analysis of multiple infections in the context of a study in which treatments may have an effect on mortality. The methods are applied to an AIDS clinical trial of prophylaxis for fungal infections.

📜 SIMILAR VOLUMES

Analysis of multiple failure time data f

Analysis of multiple failure time data from an AIDS clinical trial by Dianne M. Finkelstein, David A. Schoenfeld and Eva Stamenovic, Statistics in Medicine, 16, 951–961 (1997)

✍ Cédric Mahé 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 1 views

have presented recently an interesting paper on the way to analyse AIDS clinical trials when we have a combined endpoint of infection recurrences and death. They use one of the most famous multivariate generalizations of the proportional hazards model: the model of Wei, Lin and Weissfield (hereafter

AN OVERVIEW OF STATISTICAL METHODS FOR M

AN OVERVIEW OF STATISTICAL METHODS FOR MULTIPLE FAILURE TIME DATA IN CLINICAL TRIALS

✍ L. J. WEI; DAVID V. GLIDDEN 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB 👁 1 views

In a long term clinical trial to evaluate a new treatment, quite often each study subject may experience a number of 'failures' that correspond to repeated occurrences of the same type of event or events of entirely different natures during his/her follow-up period. To obtain efficient inference pro

Analysis of messy longitudinal data from

Analysis of messy longitudinal data from a randomized clinical trial

✍ W. Qian; M. K. B. Parmar; R. J. Sambrook; P. M. Fayers; D. J. Girling; R. J. Ste 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

Analysis of longitudinal data in an Alzh

Analysis of longitudinal data in an Alzheimer's disease clinical trial

✍ Ronald G. Thomas; Julie D. Berg; Mary Sano; Leon Thal 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Evidence of delayed progression is the primary mechanism for demonstrating therapeutic e cacy in clinical trials in Alzheimer's disease. In the major trials of therapeutic treatment of AD, to date, measures based on clinical judgement and cognitive performance, instead of mortality, have been used a

Analysis of failure times for multiple i

Analysis of failure times for multiple infections following bone marrow transplantation: an application of the multiple failure time proportional hazards model

✍ Peter J. Hannan; Xiao O. Shu; Daniel Weisdorf; Anne Goldman 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

We report an application of the proportional hazards model for multiple failure times in a study arising from the Bone Marrow Transplant Database at the University of Minnesota. The study compared the risk of infections after transplantation for patients who received allogeneic bone marrow transplan

Assessing treatment–time interaction in

Assessing treatment–time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials

✍ F. Boutitie; F. Gueyffier; S. J. Pocock; J. P. Boissel 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 1 views

Exploration of the variation of treatment effect over time in randomized clinical trials with low event rates is limited by lack of power. A meta-analysis on individual patient data from such trials can partly solve the problem, but brings other computational difficulties. Using an example in hypert